Total amount: € 0,00
Di Pierro F. 1, Rapacioli G. 1, Speroni M. 1, Callegari A. 1, Biondi M. 2, Zerbinati N. 3
1 Velleja Research, Pontenure, Piacenza
2 Dipartimento di Dermatologia, ASL Piacenza, Piacenza
3 Università di Varese, Dipartimento di Dermatologia, Varese
Polymorphous light eruption (PLE) is the most common idiopathic photodermatosis, with a prevalence of as high as 10-20% in Western Europe and in the USA. Although not life-threatening, it can severely impair patients’ quality of life; its ethiopathogenesis, triggered by UV radiation exposure, is presumably immunological. PLE is characterized clinically by the occurrence of non-scarring, pruritic, erythematous papules, vesicles or plaques mainly on sun-exposed skin areas. The aim of this study was to verify the anti-PLE action of an innovative, mainly PAF-antagonist, Ginkgo biloba-derived product administered orally to substitute the common therapy based on oral anti-histamine drugs and topical corticosteroids. Between April 1 and September 30 2008, 80 subjects (60 females and 20 males) diagnosed, in the previous three years of PLE and usually treated with protective sunscreens (SPF 20) along with anti-histamine drugs and corticosteroids, have been enrolled and treated with their usual sunscreen along with a innovative Ginkgo biloba-derived product (n=40) or with a undistinguishable placebo (n=40) twice a day for the whole length of the study. Differently from placebo, subjects treated with the usual sunscreen along with the a innovative Ginkgo biloba-derived product have shown a clear reduction of PLE symptoms, nevertheless neither anti-histamine drugs nor topical or oral corticosteroids have been used. Total PLE episodes were, out of 240 expected, 18 in the treated group and 218 in the placebo one. Compliance and tolerability were very good and no relevant side effects occurred in both groups. Obtained data suggest a primary role played by the innovative Ginkgo biloba-derived product in ethiopathogenesis of PLE and the possible chance offered by the use of the PAF-antagonists in treating PLE.
language: English, Italian